External Source
[fullver] Immunitybio Mystery: Why Did The Fda Reject Anktiva’s Label Expansion? #ibrx
Synopsis
ImmunityBio (IBRX), a U.S. immuno-oncology company, received FDA approval for its lead drug ANKTIVA in April 2024. However ...
You Might Also Like
Download Options
Choose a download method below. All links open in new tabs.
| Service | Features | Action |
|---|---|---|
| SaveFrom |
MP4 & MP3 • HD Quality • Browser Extension Available
|
Download |
Security Notice: These are third-party services. We recommend using antivirus software and being cautious of pop-up ads.